NASDAQ:MBOT - Nasdaq - US59503A2042 - Common Stock - Currency: USD
2.61
+0.18 (+7.41%)
The current stock price of MBOT is 2.61 USD. In the past month the price increased by 70.59%. In the past year, price increased by 196.59%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 26.96 | 223.47B | ||
ISRG | INTUITIVE SURGICAL INC | 67.35 | 184.36B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.74 | 150.72B | ||
SYK | STRYKER CORP | 29.95 | 139.34B | ||
MDT | MEDTRONIC PLC | 15.76 | 107.94B | ||
BDX | BECTON DICKINSON AND CO | 14.74 | 58.89B | ||
EW | EDWARDS LIFESCIENCES CORP | 29.25 | 44.70B | ||
IDXX | IDEXX LABORATORIES INC | 38.88 | 35.45B | ||
RMD | RESMED INC | 25.98 | 34.64B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.24 | 31.33B | ||
DXCM | DEXCOM INC | 43.43 | 28.10B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 15.84 | 23.53B |
Microbot Medical, Inc. is a pre-clinical medical device company engaged in the research, design, development, and commercialization of micro-robotics assisted medical technologies. The company is headquartered in Hingham, Massachusetts and currently employs 22 full-time employees. The firm is specializing in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company is primarily focused on leveraging its robotic technologies with surgical robotics to improve surgical outcomes for patients. Its technological platforms include LIBERTY and NovaCross. Using its LIBERTY Endovascular Robotic Surgical System, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. The company eliminates the need for capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. LIBERTY Endovascular Robotic Surgical System addresses the needs of interventional cardiology, interventional radiology and interventional neuroradiology markets.
MICROBOT MEDICAL INC
25 Recreation Park Dr Suite 108
Hingham MASSACHUSETTS 02043 US
CEO: Harel Gadot
Employees: 22
Company Website: http://www.microbotmedical.com/
Investor Relations: http://www.microbotmedical.com/investors/
Phone: 19089385561
The current stock price of MBOT is 2.61 USD. The price increased by 7.41% in the last trading session.
The exchange symbol of MICROBOT MEDICAL INC is MBOT and it is listed on the Nasdaq exchange.
MBOT stock is listed on the Nasdaq exchange.
7 analysts have analysed MBOT and the average price target is 9.18 USD. This implies a price increase of 251.72% is expected in the next year compared to the current price of 2.61. Check the MICROBOT MEDICAL INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
MICROBOT MEDICAL INC (MBOT) has a market capitalization of 90.67M USD. This makes MBOT a Micro Cap stock.
MICROBOT MEDICAL INC (MBOT) currently has 22 employees.
MICROBOT MEDICAL INC (MBOT) has a support level at 1.46. Check the full technical report for a detailed analysis of MBOT support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
MBOT does not pay a dividend.
MICROBOT MEDICAL INC (MBOT) will report earnings on 2025-05-13.
MICROBOT MEDICAL INC (MBOT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.74).
The outstanding short interest for MICROBOT MEDICAL INC (MBOT) is 15.87% of its float. Check the ownership tab for more information on the MBOT short interest.
ChartMill assigns a technical rating of 10 / 10 to MBOT. When comparing the yearly performance of all stocks, MBOT is one of the better performing stocks in the market, outperforming 98.74% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to MBOT. MBOT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months MBOT reported a non-GAAP Earnings per Share(EPS) of -0.74. The EPS increased by 25.25% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -189.74% | ||
ROE | -324.16% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to MBOT. The Buy consensus is the average rating of analysts ratings from 7 analysts.